A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of GLPG3667 in Adult, Healthy Male Subjects
Sponsor: Galapagos NV
Listed as NCT04976270, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Galapagos NV, it has been updated 6 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Nov 2021 — Mar 2022 [monthly]
Recruiting PHASE1
▶ Show 1 earlier version
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE1
First recorded
Jul 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Galapagos NV
For direct contact, visit the study record on ClinicalTrials.gov .